Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, marking a significant milestone in the company's innovative drug development [1][2]. Group 1: Drug Approval and Development - HSN002066C1 tablets, a selective PARP7 inhibitor, are developed by Huason Yingnuo and are intended for the treatment of advanced malignant solid tumors [1]. - The drug has shown significant tumor suppression activity in various tumor models when administered alone or in combination, with high exposure levels observed in mouse studies [1]. Group 2: Impact on the Company - HSN002066C1 is the first clinical approval for Huason Yingnuo's innovative drug project, establishing a solid foundation for the company's strategy of combining innovation and generics [2]. - The company acknowledges that the drug development process is subject to various uncertainties, including technical, regulatory, and market competition factors, which may affect the clinical trial progress and eventual market approval [2].

Core Viewpoint - Huason Pharmaceutical (002907.SZ) announced that its subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd. (referred to as "Huason Yino"), has received the Clinical Trial Approval Notice from the National Medical Products Administration for the HSN002066C1 tablet in two specifications [1] Group 1 - HSN002066C1 tablet (with free base HSN002B015) is a selective small molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) developed independently by Huason Yino, with full ownership of intellectual property rights [1] - The clinical application of HSN002066C1 is intended for the treatment of patients with advanced malignant solid tumors [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, showing significant tumor suppression activity in various tumor models when administered alone or in combination [1]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, a selective PARP7 inhibitor for treating advanced malignant solid tumors [1] Group 1 - HSN002066C1 tablets, with the free base HSN002B015, are independently developed by Huason Inno and fully owned in terms of intellectual property rights [1] - The drug is intended for oral administration and has shown significant tumor suppression activity in various tumor models when used alone or in combination [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, demonstrating high exposure levels in mice [1]